Response at three months is a good predictive factor for newly diagnosed chronic myeloid leukemia patients treated by recombinant interferon-alpha.

Abstract

In a single institution, we have used recombinant interferon- (IFN-) to treat 116 newly diagnosed Philadelphia-positive (Ph+) chronic myeloid leukemia (CML) patients and analyzed the predictive factors for response and survival. The patients whose median age was 50.3 years (range, 9 to 70) were administered IFN- (5 million units/m2/d) subcutaneously. The… (More)

Topics

10 Figures and Tables

Cite this paper

@article{Mahon1998ResponseAT, title={Response at three months is a good predictive factor for newly diagnosed chronic myeloid leukemia patients treated by recombinant interferon-alpha.}, author={F X Mahon and C Fab{\'e}res and Sophie Pueyo and Pascale Cony-Makhoul and Roberta Salmi and Jean Michel Boiron and Gary B Marit and Chryst{\'e}le Bilhou-Nabera and Am{\'e}lie Carrere and Marion Montastruc and Arnaud Pigneux and Philip A. Bernard and Jonas Reiffers}, journal={Blood}, year={1998}, volume={92 11}, pages={4059-65} }